profit from every A$100 of sales.
A$0A$100
EBOS Group
A$17.57-0.57% today
-26.2% in 1 year
1-year low A$14.961-year high A$24.55
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay A$15.86 for every A$1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What EBOS Group sold, what it kept, and what it did with the cash.
Sales went from A$11.9 billion in 2022 to A$13.2 billion in 2025, with A$232 million of profit last year.
SalesProfit
EBOS Group handed back 37% of the cash it generated last year.
A$148M
Free cash flow 2025A$396M
Bought back its own shares–
Paid as dividendsA$148M
Cash vs. debtA$198M vs. A$1.7B
EBOS Group vs. similar companies
EBOS Group grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from A$100 of sales | Sales growth a year | Price per A$1 of profit |
|---|---|---|---|
| EBOS Group | 15.9× · Fair price | ||
 McKesson | 26.7× · Fair price | ||
 Cencora | 44.1× · Expensive | ||
 Cardinal Health | 41.6× · Expensive | ||
 Sigma Healthcare | 63.0× · Very expensive |
AI analysis
An AI analyst reads EBOS Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 11,902 | 13,317 | 14,411 | 13,209 | |
| 1,381 | 1,699 | 1,784 | 1,763 | |
| 395 | 499 | 527 | 456 | |
| 444 | 616 | 650 | 580 | |
| 225 | 276 | 297 | 232 | |
| 1.27 | 1.45 | 1.54 | 1.17 | |
| 11.6% | 12.8% | 12.4% | 13.3% | |
| 3.3% | 3.7% | 3.7% | 3.4% | |
| 1.9% | 2.1% | 2.1% | 1.8% |
Balance sheet
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 6,946 | 7,005 | 7,369 | 7,837 |
| Cash | 574 | 231 | 237 | 198 |
| Total debt | 1,827 | 1,396 | 1,795 | 1,746 |
| Total liabilities | 4,560 | 4,499 | 4,726 | 4,904 |
| 2,511 | 2,649 | 2,678 | 2,950 | |
| 177 | 191 | 192 | 197 | |
| 5.7% | 8.3% | 8.0% | 6.3% | |
| 8.9% | 10.4% | 11.1% | 7.9% |
Cash flow
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| 99 | 107 | 92 | 54 | |
| 176 | 319 | 288 | 396 | |
| Dividends paid | 171 | 191 | 171 | 148 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 15.9×
- –
- –
- 1.1×
- 0.3×
- 9.3×
- 9.0×
- 10.8%
- 6.3%
- 4.0%
Profitability
- 13.3%
- 3.4%
- 1.8%
- –
- 6.0%
- 7.1%
- –
- –
- –
- –
Growth
- +3.5%
- −2.6%
- –
- –
- +2.7%
Financial health
- 2.9×
- 0.69
- –
- 4.1×
- 1.16
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 50%of 963
Bottom 30%of 894
Top 23%of 632
Bottom 25%of 908
Top 7%of 991
4.0%of the share price, paid each year
On $1,000 invested$40a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
63.7% of its profit
Room to growStretchedMore than it earns: 37.2%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
71Pass
Philip Fisher
29No pass
Peter Lynch
19No pass
Joel Greenblatt
37No pass
Charlie Munger
22No pass
Terry Smith
28No pass
Questions about EBOS Group
Is EBOS Group a good stock to buy?
A business with weak numbers at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the EBOS Group AI analysis
What does EBOS Group do?
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through the Healthcare and Animal Care segments. It is in Medical Distribution, based in Docklands, VIC, Australia, with 5,800 employees.
Does EBOS Group pay a dividend?
Yes. At today's price the dividend is 4.0% a year, about 64% of its yearly profit. In 2025 it paid out A$148 million in dividends.
Is EBOS Group stock halal?
No. EBOS Group does not pass our halal screen: its debt is 48% of its market value, at or above the 33% limit. How we check
How has EBOS Group stock done over the past year?
Down 26.2% over the past twelve months, to A$17.57. It traded between A$14.96 and A$24.55 and is 28.4% below its high.
Who are EBOS Group's competitors?
The largest listed companies in the same industry are McKesson, Cencora, Cardinal Health and Sigma Healthcare. The peers table on this page compares their profit, growth and price with EBOS Group's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.